NQF adds quality measures to behavioral health portfolio

The National Quality Forum (NQF) has endorsed six new behavioral health quality measures and reaffirmed its support for four existing measures related to substance abuse, adherence to antipsychotic medication and post-discharge care coordination for patients hospitalized for mental illness.

NQF is engaged in an ongoing evaluation and updating of new and existing measures to ensure that all included in the behavioral health portfolio are “best in class” that address gaps in care delivered and align with national priorities, according to a Nov. 5 statement.

The recently endorsed measures are listed in a written statement from NQF and requests they be reconsidered can be made by submitting, no later than Dec. 4, an appeal on the NQF measure database.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.